The Australian share market begins the week with a slightly stronger opening without being affected by a flat lead from Wall Street. In early trade, Gold and Financial stocks were positive after the opening bell.
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the Australian Therapeutic Goods Administration (TGA) has issued a licence to Mesoblast to manufacture and supply its proprietary Mesenchymal Precursor Cells (MPC) products.
The Australian market dropped sharply at opening on Monday following a plunge in Wall Street Friday. The Dow Jones Industrial Average tumbled 2.52 per cent Friday after disappointing earnings reports from Bank of America, Citigroup and General Electric. Sharp falls in consumer confidence data also fueled concerns on US economy recovery.
Benitec Limited (ASX:BLT) (PINK:BNIKF) are pleased to provide this update on the progress of the patent family "Control of Gene Expression" in a number of countries around the world. The "Control of Gene Expression" patents are part of the foundational Graham RNAi patent family.
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that based on positive results from its bone marrow transplant clinical trial, conducted at the University of Texas MD Anderson Cancer Center, a formal meeting has been scheduled with the United States Food and Drug Administration (FDA) to discuss a proposed Phase 3 clinical trial program.
Benitec Limited (ASX:BLT) (PINK:BNIKF) are pleased to announce that US Patent 7727970 "Multiple promoter expression cassettes for simultaneous delivery of RNAi agents targeted to Hepatitis C virus" has been granted by the United States Patent and Trademark Office (USPTO). The granted claims cover the use of an RNA interference construct (with multiple promoters) to inhibit the level of Hepatitis C virus in animal cells, tissues and organs. Moreover, the USPTO has granted Benitec an additional 805 days patent term in recognition of the delays in examining the patent application. Additional related applications remain pending to extend the scope of protection.
Benitec Limited (ASX:BLT) (PINK:BNIKF) are pleased to announce that the results of Benitec's US-based HIV/AIDS pilot clinical trial have been published in the prestigious scientific journal Science Translational Medicine, a journal published by the American Association for the Advancement of Science.
